SignatureFD
ANIK icon

SignatureFD’s Anika Therapeutics ANIK Stock Holding History

SignatureFD’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79
Closed -$1.95K – 3310
2024
Q3 		$1.95K Sell
79
-118
-60% -$3.06K ﹤0.01% 2838
2024
Q2 		$4.99K Buy
197
+94
+91% +$2.44K ﹤0.01% 2519
2024
Q1 		$2.62K Buy
103
+18
+21% +$436 ﹤0.01% 2732
2023
Q4 		$1.93K Buy
+85
New +$1.76K ﹤0.01% 2772
2023
Q3 		– Sell
-55
Closed -$1.43K – 3200
2023
Q2 		$1.43K Hold
55
– – ﹤0.01% 2892
2023
Q1 		$1.58K Hold
55
– – ﹤0.01% 2869
2022
Q4 		$1.63K Buy
55
+50
+1,000% +$1.42K ﹤0.01% 2868
2022
Q3 		$0 Sell
5
-55
-92% -$1.27K ﹤0.01% 3101
2022
Q2 		$1K Buy
+60
New +$1.34K ﹤0.01% 2868
2020
Q4 		– Sell
-20
Closed -$1K – 2544
2020
Q3 		$1K Buy
+20
New +$722 ﹤0.01% 2356

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

SignatureFD's ANIK Position: Q4 2024 in Review

SignatureFD sold out of Anika Therapeutics (ANIK) in Q4 2024, closing a stake of 79 shares — an estimated $1.95K sold.

SignatureFD first reported a position in ANIK in Q3 2020 and held it in 10 quarters. The position peaked at $4.99K in Q2 2024. 109 funds tracked by Wall St. Rank hold ANIK as of Q4 2024.

  • SignatureFD reported no remaining Anika Therapeutics position as of Q4 2024 after selling out during the quarter.
  • SignatureFD sold 79 Anika Therapeutics shares in Q4 2024, an estimated $1.95K.
  • SignatureFD first reported a position in Anika Therapeutics in Q3 2020 and held it in 10 quarters.
  • SignatureFD's Anika Therapeutics position peaked at $4.99K in Q2 2024.
  • 109 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2024.

Based on SignatureFD's 13F filing for Q4 2024, filed 10 Feb 2025.